Navigation Links
Building the lymphatic drainage system
Date:4/26/2009

Our bodies' tissues need continuous irrigation and drainage. Blood vessels feeding the tissues bring in the fluids, and drainage occurs via the lymphatic system. While much is known about how blood vessels are built, the same was not true for lymph vessels. Now though, Norrmn et al. have identified two of the lead engineers that direct drainage construction in the mouse embryo.

The engineers are the transcription factors, Foxc2 and NFATc1. Foxc2 had been implicated in lymph vessel development already, but Norrmn and colleagues have now found that the factor specifically regulates a late stage of lymph development when large, valve-containing vessels arise from more primitive capillaries. The study will be published online April 27 (www.jcb.org) and will appear in the May 4 print issue of the Journal of Cell Biology.

Foxc2 built the lymph vessel valves with the help of NFATc1, which was a known heart valve engineer. Norrmn and colleagues also showed that Foxc2 and NFATc1 physically interact and that many DNA binding sites for the two transcription factors are closely linked. This latter finding generated a long list of target genes that might be controlled by the two factors.

The team now plans to investigate these targets as well as to work out the upstream molecular pathways controlling Foxc2 and NFATc1. Whatever the mechanisms, if the team can show that Foxc2 and NFATc1 also prompt lymph vessel regeneration in adults, boosting these factors could help patients with lymph drainage problems including those that have suffered extensive tissue injuries, or have had lymph nodes removed as part of cancer treatment.


'/>"/>

Contact: Rita Sullivan
news@rupress.org
212-327-8603
Rockefeller University Press
Source:Eurekalert  

Page: 1

Related biology news :

1. Stevens hosts Green Building: The Bottom Line, April 8
2. Brain building: Study shows brain growth tied to cell division in mouse embryos
3. CSHL researchers pinpoint structure-building role for 2 non-coding RNAs
4. Building strong bones: Running may provide more benefits than resistance training, MU study finds
5. Cell-building discovery could reduce need for some animal research
6. Building better bones and tissue in the lab
7. Building the blood-brain barrier
8. Building a better bee
9. Building a stronger roof over your head: 3 little pigs project begins first tests
10. Green roofs differ in building cooling, water handling capabilities
11. Building bridges between the clinic and the laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Building the lymphatic drainage system
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... 20 August 2010 - Pharma-Nutrition, the new international ... of scientific, technical and medical information products and ... and practical applications of medical nutrition in patient ... is set to take place next 18-20 April ...
... CHAPEL HILL Researchers at the University of North Carolina ... architecture controlling the growth of the collateral circulation the ... in the event of a heart attack or stroke. ... what are called collaterogenic therapies drugs or procedures that ...
... Four" Sherlock Holmes tells Watson he has written a monograph ... plates illustrating the difference in the ash." He finds the ... smoke during the commission of a crime. But Sherlock ... a patch on geologists and the "redox proxies" from which ...
Cached Biology News:Genetics underlie formation of body's back-up bypass vessels 2Geologists revisit the Great Oxygenation Event 2Geologists revisit the Great Oxygenation Event 3Geologists revisit the Great Oxygenation Event 4Geologists revisit the Great Oxygenation Event 5Geologists revisit the Great Oxygenation Event 6
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... ... 01, 2015 , ... A newly launched business plan contest will ask startup ... innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see ... a period of expert mentorship from a senior industry figure drawn from the Pistoia ...
(Date:7/1/2015)... ... 01, 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker ... , The presentation took place on Tuesday, June 16 and provided an update ... APX3330 for the treatment of pancreatic cancer. A copy of the company overview ...
(Date:7/1/2015)... July 1, 2015  UCB, a multinational biopharmaceutical ... global leader in designing, transforming, and running intelligent ... in recognition of their close collaboration in driving ... global business services (GBS) finance organization. ... clients that work together effectively to embrace the ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... (NASDAQ: AMGN ) today announced the submission of ... and Drug Administration (FDA) to expand the indication for XGEVA® ... the risk of developing bone metastases. If approved, XGEVA would ... spread of cancer to the bone. The ...
... June 27, 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ... arising out of a blog post on Friday, June ... the Company,s common stock fell more than 20% and ... (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b) The author of the blog ...
... Md., June 27, 2011 PharmAthene, Inc. (NYSE Amex: ... achieved an important technical milestone in its recombinant protective ... initial technology transfer of its manufacturing process for the ... the 100 liter scale to a US-based manufacturing facility ...
Cached Biology Technology:Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 2Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 3Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 4Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 5Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 6Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 7Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 8Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 9Generex Provides Clarification of Facts 2Generex Provides Clarification of Facts 3Generex Provides Clarification of Facts 4Generex Provides Clarification of Facts 5PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer 2PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer 3
Bovine Serum...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
2.0 GHz Compaq Computer with 512 MB RAM, 32 MB AGP Graphics Card, 40 GB Hard Drive, 1 Serial Port & Open PCI Slot, Windows 2000 OS, MS Office, CD Read/Writer and 18 Flat Panel Monitor...
Quartz-Halogen, 100 W, High Intensity...
Biology Products: